Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intravenous difelikefalin pharmacokinetics study in adolescents on hemodialysis
2021-000894-94Phase 2Terminated
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Vifor Fresenius Medical Care Renal Pharma. Primary endpoint: Pharmacokinetics profile of difelikefalin after a single dose post haemodialysis. Started Aug 2021; status: terminated.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2021-000894-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000894-94.